Andrew D J Pearson
Affiliation: Institute of Cancer Research
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trialAndrew D J Pearson
Children s Department, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
Lancet Oncol 9:247-56. 2008..We aimed to assess whether an intensive chemotherapy protocol that had a 10-day interval between treatments would improve event-free survival (EFS) in patients aged 1 year or over with high-risk neuroblastoma...
- Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experienceLucas Moreno
Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Pediatr Blood Cancer 60:1135-40. 2013..The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial...
- Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine gliomaFernando Carceller
Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
J Neurooncol 129:109-21. 2016..107-0.882; p = 0.028) in DIPG. PsP occurred in both pediatric HGG and DIPG patients at a comparable rate to adult HGG. PsP was associated with improved 1-yr PFS in HGG patients. PsP had a protective effect upon OS in DIPG patients. ..
- Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk NeuroblastomaDominik Schrey
Children and Young People s Unit Department of Nuclear Medicine and PET CT, The Royal Marsden NHS Foundation Trust Divisions of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK Clinical Research Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain
J Pediatr Hematol Oncol 37:e150-3. 2015..It is therefore proposed to develop stratification criteria for those patients very unlikely to benefit from a plethora of additional lines of treatment, but might benefit from introduction of novel agents. ..
- Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastomaSally L George
aChildren s and Young Persons Unit bJoint Department of Physics, Institute of Cancer Research, Royal Marsden NHS Foundation Trust cDepartment of Nuclear Medicine, The Royal Marsden Hospital, Surrey, UK
Nucl Med Commun 37:466-72. 2016..We evaluate response and toxicity following a dosimetry-based, individualized approach...
- Targeted approaches to childhood cancer: progress in drug discovery and developmentSteffen Hirsch
The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, SM2 5PT, UK 44 0 20 8915 6161
Expert Opin Drug Discov 10:483-95. 2015..Drug development in paediatric oncology has specific requirements with regard to the patient population and the regulatory background and presents several unique challenges that need addressing...
- MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom
Curr Drug Targets 15:114-23. 2014..In conclusion, targeting the interaction between p53 and its main negative regulator MDM2 represents a major new therapeutic approach in poor prognosis paediatric malignancies without p53 mutations. ..
- p53 is nuclear and functional in both undifferentiated and differentiated neuroblastomaLindi Chen
Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
Cell Cycle 6:2685-96. 2007..In conclusion, p53 is predominantly nuclear and functional in neuroblastoma regardless of differentiation status...
- Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapseJane Carr
Northern Institute for Cancer Research, University of Newcastle upon Tyne, United Kingdom
Cancer Res 66:2138-45. 2006..If these data are confirmed in neuroblastoma tumors, this suggests that p53-independent therapy and reactivation of inactive p53 approaches would be useful in the management of relapsed neuroblastoma...
- Regions syntenic to human 17q are gained in mouse and rat neuroblastomaMaria Łastowska
Institute of Human Genetics, International Centre for Life, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
Genes Chromosomes Cancer 40:158-63. 2004..2 Mb from the previously defined region of 17q gain in humans as a likely location of the candidate gene or genes, and strongly suggests that the molecular etiology of neuroblastoma is similar in all three species...
- Cyclophosphamide metabolism in children with non-Hodgkin's lymphomaS Murray Yule
Department of Child Health, Yorkhill National Health Service Trust, Glasgow, United Kongdom
Clin Cancer Res 10:455-60. 2004..The purpose of our study was to determine whether variation in cyclophosphamide metabolism influences the incidence of recurrence among children receiving chemotherapy for B-cell non-Hodgkin's lymphoma...
- Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behaviorTamas Tornoczky
Department of Pathology, Faculty of Medicine, Medical and Health Sciences Center, University of Pecs, Szigeti ut 12, H 7643 Pecs, Hungary
Cancer 100:390-7. 2004....
- Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumorsSean Carlin
Departments of Radiation Oncology and Child Health, University of Glasgow, Cancer Research UK Beatson Laboratories, Glasgow G61 1BD, United Kingdom
Clin Cancer Res 9:3338-44. 2003..EXPERMENTAL DESIGN: Tumor specimens from 54 neuroblastoma patients were analyzed using real-time PCR, and NAT expression was compared with the corresponding diagnostic scintigrams...
- The p53 pathway and its inactivation in neuroblastomaDeborah A Tweddle
Cancer Research Unit, The Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
Cancer Lett 197:93-8. 2003..If p53 inactivation occurs frequently in relapsed tumours it may be appropriate to include p53 independent therapies in the initial management of high-risk neuroblastoma...
- Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expressionQuentin Campbell Hewson
Department of Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
J Cell Biochem 87:284-91. 2002..The possibility that RXR-homodimers mediate, in part, the induction of CRABP-II by 9-cis RA and RXR-specific ligands is discussed...
- Breakpoint position on 17q identifies the most aggressive neuroblastoma tumorsMaria Łastowska
Institute of Human Genetics, International Centre for Life, University of Newcastle upon Tyne, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK
Genes Chromosomes Cancer 34:428-36. 2002..1 and 17qter acting to promote tumor progression...
- Retinoid X receptors and retinoid response in neuroblastoma cellsBirju Rana
Department of Endocrinology, Medical Molecular Biology Group, Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
J Cell Biochem 86:67-78. 2002..The results of this study suggest that interactions between retinoid receptors and other nuclear proteins may be critical determinants of retinoid responses in neural cells...
- Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cellsGareth J Veal
Cancer Research Unit, Medical School, University of Newcastle upon Tyne, NE2 4HH, Newcastle upon Tyne, UK
Biochem Pharmacol 63:207-15. 2002..In summary, these results indicate either an intracellular conversion of 13-cis RA to ATRA or a selective uptake of ATRA and suggest that this may mediate the differential activity of 13-cis RA in neuroblastoma cell subtypes...